Compare OXSQ & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OXSQ | MSLE |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 154.6M |
| IPO Year | N/A | N/A |
| Metric | OXSQ | MSLE |
|---|---|---|
| Price | $1.44 | $9.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 97.8K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $5.44 |
| 52 Week High | $2.42 | $13.39 |
| Indicator | OXSQ | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 66.72 |
| Support Level | $1.26 | $6.71 |
| Resistance Level | $1.95 | $13.39 |
| Average True Range (ATR) | 0.06 | 0.82 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 18.18 | 73.42 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.